Literature DB >> 16751374

Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors.

Marco A Purbhoo1, Deborah H Sutton, Joanna E Brewer, Rebecca E Mullings, Maxine E Hill, Tara M Mahon, Julia Karbach, Elke Jäger, Brian J Cameron, Nikolai Lissin, Paresh Vyas, Ji-Li Chen, Vincenzo Cerundolo, Bent K Jakobsen.   

Abstract

Presentation of intracellular tumor-associated Ags (TAAs) in the context of HLA class I molecules offers unique cancer-specific cell surface markers for the identification and targeting of tumor cells. For most peptide Ags, the levels of and variations in cell surface presentation remain unknown, yet these parameters are of crucial importance when considering specific TAAs as targets for anticancer therapy. Here we use a soluble TCR with picomolar affinity for the HLA-A2-restricted 157-165 epitope of the NY-ESO-1 and LAGE-1 TAAs to investigate presentation of this immunodominant epitope on the surface of a variety of cancer cells. By single molecule fluorescence microscopy, we directly visualize HLA-peptide presentation for the first time, demonstrating that NY-ESO-1/LAGE-1-positive tumor cells present 10-50 NY-ESO-1/LAGE-1(157-165) epitopes per cell.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751374     DOI: 10.4049/jimmunol.176.12.7308

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

Review 1.  Mechanisms and functions for the duration of intercellular contacts made by lymphocytes.

Authors:  Daniel M Davis
Journal:  Nat Rev Immunol       Date:  2009-07-17       Impact factor: 53.106

2.  TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.

Authors:  Devin B Lowe; Camille K Bivens; Alexis S Mobley; Christian E Herrera; Amanda L McCormick; Timea Wichner; Manoj K Sabnani; Laurence M Wood; Jon A Weidanz
Journal:  MAbs       Date:  2017 May/Jun       Impact factor: 5.857

3.  Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.

Authors:  G de Jong; L Bartels; M Kedde; E M E Verdegaal; M A Gillissen; S E Levie; M G Cercel; S E van Hal-van Veen; C Fatmawati; D van de Berg; E Yasuda; Y B Claassen; A Q Bakker; S H van der Burg; R Schotte; J Villaudy; H Spits; M D Hazenberg; P M van Helden; K Wagner
Journal:  Cancer Immunol Immunother       Date:  2020-11-23       Impact factor: 6.968

Review 4.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

5.  ImmTACs: Novel bi-specific agents for targeted cancer therapy.

Authors:  Joanne Oates; Bent K Jakobsen
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

6.  Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.

Authors:  Tomohide Tsukahara; Makoto Emori; Kenji Murata; Takahisa Hirano; Norihiro Muroi; Masanori Kyono; Shingo Toji; Kazue Watanabe; Toshihiko Torigoe; Vitaly Kochin; Hiroko Asanuma; Hiroshi Matsumiya; Keiji Yamashita; Tetsuo Himi; Shingo Ichimiya; Takuro Wada; Toshihiko Yamashita; Tadashi Hasegawa; Noriyuki Sato
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

7.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Authors:  Gerald P Linette; Edward A Stadtmauer; Marcela V Maus; Aaron P Rapoport; Bruce L Levine; Lyndsey Emery; Leslie Litzky; Adam Bagg; Beatriz M Carreno; Patrick J Cimino; Gwendolyn K Binder-Scholl; Dominic P Smethurst; Andrew B Gerry; Nick J Pumphrey; Alan D Bennett; Joanna E Brewer; Joseph Dukes; Jane Harper; Helen K Tayton-Martin; Bent K Jakobsen; Namir J Hassan; Michael Kalos; Carl H June
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

8.  Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Authors:  Valéria C C Andrade; André L Vettore; Roberta S Felix; Manuella S S Almeida; Fabrício Carvalho; José Salvador R Oliveira; Maria Lourdes Lopes Ferrari Chauffaille; Adagmar Andriolo; Otavia L Caballero; Marco Antonio Zago; Gisele W B Colleoni
Journal:  Cancer Immun       Date:  2008-02-01

9.  Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

Authors:  Paul F Robbins; Yong F Li; Mona El-Gamil; Yangbing Zhao; Jennifer A Wargo; Zhili Zheng; Hui Xu; Richard A Morgan; Steven A Feldman; Laura A Johnson; Alan D Bennett; Steven M Dunn; Tara M Mahon; Bent K Jakobsen; Steven A Rosenberg
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

10.  Can oligomeric T-cell receptor be used as a tool to detect viral peptide epitopes on infected cells?

Authors:  Nadia Anikeeva; Tatiana Mareeva; Wei Liu; Yuri Sykulev
Journal:  Clin Immunol       Date:  2008-10-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.